

# INFECTION CONTROL



## EDITORIAL

### **Intravenous Fluid Contamination, Aegean-Style**

Donald A. Goldmann, MD

## ORIGINAL ARTICLES

### **Enterobacter Sepsis in Infants and Children Due to Contaminated Intravenous Fluids**

Nikos S. Matsaniotis, MD; Vassiliki Ph. Syriopoulou, MD;  
Maria Ch. Theodoridou, MD; Konstantina G. Tzanetou, MD;  
Glyceria I. Mostrou, MD

### **Rotavirus Infection in Normal Nursery: Epidemic and Surveillance**

G. Srinivasan, MD; E. Azarcon, BSN, MEd; M.R.L. Muldoon, PhD;  
G. Jenkins, BSN, MPH; S. Polavarapu, MD; C.A. Kallick, MD;  
R.S. Pildes, MD

### **Caring for the Infectious Patient: Risk Factors During Pregnancy**

Inge Gurevich, RN, MA; Patricia Tafuro, RN, BSN

### **Evaluation of Skin Antisepsis Prior to Blood Culture in Neonates**

Sylvie Champagne, MD; Susan Fussell, NZCS;  
David Scheifele, MD

### **Clinical Pharmacology of Antibiotics: The Cephalosporin Antibiotic Agents- I. Considered as a Group**

T. Donald Marsh, PharmD

### **Infection Control and Employee Health: A Combined Program in Operation**

Mary Ellen Beideman, RN, BSN, CIC; Rose Haas, RN

# Safe for Scopes



## HEPATITIS

**Sporicidin, diluted 1:16, inactivates the Hepatitis B Virus in 10 minutes.**

*(Centers for Disease Control, Phoenix, Arizona)*

Courtesy of Olympus and ACMI

**Completely disinfects flexible and rigid scopes in 10 minutes with only 0.13% glutaraldehyde.**

**Safe to use . . .** Does not cloud scope lenses nor harm metals, rubber and/or plastics. Does not stain or irritate the hands. No gloves are necessary for safety. Vapors do not irritate the eyes or nostrils.

**Most effective . . .** The only sterilizing solution which is fully effective against the tubercle bacillus, influenza, hepatitis and enteroviruses when diluted 1 in 16.

**Stable . . .** Fully effective for 30 days after activation.



**The Sporicidin Company**

4000 Massachusetts Avenue, NW, Washington, DC 20016 Call Toll Free (800) 424-3733

**Proven . . . The most effective cold sterilant and disinfectant ever registered by the E.P.A.**

**“Sporicidin, diluted 1 in 16, (0.13% glutaraldehyde), is effective for high level hospital disinfection . . .”**

*Centers for Disease Control, Atlanta, GA  
(Guidelines . . . revised August 1982)*

**“This study has determined that although E.P.A. requirements for classifying a sterilizing agent were satisfied by Cidex, they were exceeded by Sporicidin.”**

*Journal of Dental Research, Vol. 60, March 1981  
(U.S. Army Institute of Dental Research, Wash., DC)*

**“Sporicidin . . . was both more stable and more active against test spores than . . . Cidex and Cidex-7.”**

*Infection Control, 1(2): 90-93, 1980*

# INFECTION CONTROL

## Table of Contents

### Editorial

- Intravenous Fluid Contamination, Aegean-Style** 469  
Donald A. Goldmann, MD

### Original Articles

- Enterobacter Sepsis in Infants and Children Due to Contaminated Intravenous Fluids** 471  
Nikos S. Matsaniotis, MD; Vassiliki Ph. Syriopoulou, MD;  
Maria Ch. Theodoridou, MD; Konstantina G. Tzanetou, MD;  
Glyceria I. Mostrou, MD

- Rotavirus Infection in Normal Nursery: Epidemic and Surveillance** 478  
G. Srinivasan, MD; E. Azarcon, BSN, MEd; M.R.L. Muldoon, PhD;  
G. Jenkins, BSN, MPH; S. Polavarapu, MD; C.A. Kallick, MD;  
R.S. Pildes, MD

- Caring for the Infectious Patient: Risk Factors During Pregnancy** 482  
Inge Gurevich, RN, MA; Patricia Tafuro, RN, BSN

- Evaluation of Skin Antisepsis Prior to Blood Culture in Neonates** 489  
Sylvie Champagne, MD; Susan Fussell, NZCS; David Scheifele, MD

- Clinical Pharmacology of Antibiotics: The Cephalosporin Antibiotic Agents—I. Considered as a Group** 493  
Sandra M. Norris, PharmD

- Infection Control and Employee Health: A Combined Program in Operation** 498  
William M. Valenti, MD

### Departments

- |                               |     |                               |     |
|-------------------------------|-----|-------------------------------|-----|
| <b>Information to Authors</b> | 464 | <b>Calendar of Events</b>     | 501 |
| <b>Letters to the Editor</b>  | 465 | <b>Classified Marketplace</b> | 504 |
| <b>Book Reviews</b>           | 500 |                               |     |

---

**The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.**

---

**Publisher:** Infection Control (ISSN-0195-9417) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. Telephone: Thorofare (609) 848-1000.

**Copyright 1984:** All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

**Subscriptions:** Subscription requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Scope Incorporated, 11-11, Shoto 2-chrome, Shibuya-Ku, Tokyo 150, Japan. Annual subscription price is: Individual: One year—\$35.00; Two years—\$50.00; Three years—\$65.00. Institutional: One year—\$50.00; Two years—\$65.00; Three years—\$80.00. All subscriptions, without exception, will start with the first issue published after the order is received. Back copies are available, but must be purchased separately. Cost per individual copy is \$5.00. Foreign subscribers add \$15.00 to regular rate: foreign orders, \$6.00.

**Change of address:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086. **Postmaster:** Form 3547 to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.

As of Volume 1, Number 1, INFECTION CONTROL is listed in *Index Medicus*, *Current Contents—Clinical Practice*, *Hospital Literature Index*, and *Cumulative Index to Nursing and Allied Health Literature*.

# 10 Reasons for Warming Up to a Cold Sterilant Wavicide-01®

1. The *least* expensive sterilant on the market.
2. Approved as a disinfectant, using a 1:4 dilution at room temperature.
3. Ready to use, Wavicide-01 works without an activator.
4. Sporicidal, as proven by AOAC test, at 25°C (10 hrs), 40°C (5 hrs) and 60°C (1 hr).
5. Approved for use in high-power ultrasonic cleaners.
6. Proven effective in continuous 28 day use and re-use with ultrasonic systems, even in the presence of organic matter.
7. Odorless when used as a disinfectant.
8. Will not yellow hands (some disinfectants do).
9. Will not fog or corrode fiberscopes.
10. Stable, long life, *balanced glutaraldehyde* formulation.

For literature or ordering information please contact:  
Wave Energy Systems, Inc.  
130 East 59 Street, 14 Floor  
New York, NY 10022  
(212) 593-3213

➔ Wave Energy Systems Inc.



# INFECTION CONTROL / Editorial Board

## EDITOR

**Richard P. Wenzel, MD**  
Charlottesville, Virginia

## SENIOR ASSOCIATE EDITOR

**William Schaffner, MD**  
Nashville, Tennessee

## ASSOCIATE EDITORS

**Sue Crow, RN, MSN**  
Shreveport, Louisiana

**John E. McGowan, Jr., MD**  
Atlanta, Georgia

**Dennis G. Maki, MD**  
Madison, Wisconsin



SLACK Incorporated  
6900 Grove Road  
Thorofare, New Jersey 08086

## Publisher

Richard N. Roash

## Managing Editor

Donna Carpenter

## Consulting Editor

Eric Baloff

## Assistant Editor

Linda L. Jones

## Circulation Manager

Kevin J. Fenton

## Advertising Manager

Melissa Warner

## Advertising

## Sales Representative

Wayne McCourt

## Classified

## Advertising Representative

Harriet E. Hampton

## EDITORIAL

### ADVISORY BOARD

Robert C. Aber, MD  
Hershey, Pennsylvania

Charles S. Bryan, MD  
Columbia, South Carolina

John P. Burke, MD  
Salt Lake City, Utah

Marie B. Coyle, PhD  
Seattle, Washington

Burke A. Cunha, MD  
Mineola, New York

Richard E. Dixon, MD  
Trenton, New Jersey

Harvey A. Elder, MD  
Loma Linda, California

Bruce Farber, MD  
Pittsburgh, Pennsylvania

Peter C. Fuchs, MD, PhD  
Portland, Oregon

Richard A. Garibaldi, MD  
Farmington, Connecticut

Donald A. Goldmann, MD  
Boston, Massachusetts

Dieter H.M. Gröschel, MD  
Charlottesville, Virginia

Peter A. Gross, MD  
Hackensack, New Jersey

Karen Hadley, RN, MPH  
New Orleans, Louisiana

David K. Henderson, MD  
Bethesda, Maryland

Peter N.R. Heseltine, MD  
Los Angeles, California

Cyrus C. Hopkins, MD  
Boston, Massachusetts

Allen B. Kaiser, MD  
Nashville, Tennessee

Harold Laufman, MD, PhD  
New York, New York

William J. Ledger, MD  
New York, New York

Barbara McArthur, RN, PhD  
Detroit, Michigan

Rob Roy MacGregor, MD  
Philadelphia, Pennsylvania

C. Glen Mayhall, MD  
Richmond, Virginia

Ronald Lee Nichols, MD  
New Orleans, Louisiana

Harry C. Nottebart, Jr., JD, MD  
Richmond, Virginia

James E. Peacock, Jr., MD  
Winston-Salem, North Carolina

Frank S. Rhame, MD  
Minneapolis, Minnesota

William A. Rutala, PhD, MPH  
Chapel Hill, North Carolina

William E. Scheckler, MD  
Madison, Wisconsin

Robert J. Shannon, MSPH  
Boston, Massachusetts

Walter E. Stamm, MD  
Seattle, Washington

Charles W. Stratton, MD  
Nashville, Tennessee

Timothy R. Townsend, MD  
Baltimore, Maryland

William M. Valenti, MD  
Rochester, New York

James Veazey, MD  
Albany, New York

Kathy J. Wydra, RN  
Geneva, New York

## FOREIGN ADVISORY BOARD

Graham Ayliffe, MD, FRC Path.  
Birmingham, England

Professor G. Berencsi  
Szeged, Hungary

Professor Jaap Dankert  
Groningen, Netherlands

Professor Dr. F. Daschner  
Freiburg, West Germany

Lars O. Kallings, MD  
Stockholm, Sweden

Professor W.B. Kędzias  
Sieroca, Poland

Professor A.P. Krasilnikow  
Minsk, USSR

Professor Dr. W. Marget  
Munich, West Germany

Bertil Nyström, MD  
Huddinge, Sweden

Ian Phillips, MA, MD, MRC Path.  
London, England

Samuel Ponce de Leon, MD  
Mexico City, Mexico

Hans Reber, MD  
Basel, Switzerland

Professor Gerald Reybrouck  
Leuven, Belgium

Manfred L. Rotter, MD, DipBact  
Vienna, Austria

Theodore Sacks, MD  
Jerusalem, Israel

Dr. Bernhard M. Thimm  
Federal Republic of Germany

Professor Dr. med. H.P. Werner  
Mainz, West Germany

Professor Dr. W. Weuffen  
Greifswald, German Democratic Republic